TBIO - Telesis Bio Operating income before deduction of amortization
Telesis Bio, Inc. (TBIO) is developing an IT ecosystem for gene printing by locking laboratories into proprietary consumables. This eco-friendly approach reduces the carbon footprint by localizing DNA synthesis. Revenue is based on the sale of BioXp systems. EBITDA analytics demonstrate cash generation dynamics, where the level captures the current state of operating profit, helping to avoid purchasing the asset at historical peaks.
Telesis Bio (TBIO) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- market capitalization statistics:
- balance sheet equity data:
- debt level and financial liquidity data:
Debt to Equity Telesis Bio, Inc.|TBIO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Telesis Bio Inc.|TBIO - Company Debts|Debts to Book Value Telesis Bio|TBIO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Telesis Bio|Interim Coverage Ratio telesisbio.com
- company profitability and valuation multiples indicators:
TBIO - Company Net Income|Net Profit Forecast Telesis Bio, Inc.|TBIO - P/E Multiple|Projected Price to Earnings telesisbio.com|TBIO - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Telesis Bio|TBIO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Telesis Bio|TBIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months telesisbio.com|TBIO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Telesis Bio, Inc.
Analysis of all company metrics:Telesis Bio, Inc.
Absolute operating profit captures the daily liquidity inflow from core operations, allowing investors to differentiate actual cash flow from accounting accruals and identify value trap risks. By analyzing the absolute EBITDA volume, one can assess the monetization efficiency of Telesis Bio (TBIO) DNA synthesizers, whose implementation in scientific research reduces the carbon footprint by optimizing reagent logistics.
Competitor analysis for Telesis Bio, Inc.
Operating income before deduction of amortization Tempus (TEM)|Qiagen N.V. - Operating profit EBITDA|Operating income before deduction of amortization ionispharma.com IONS|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|RNA - Operating income before deduction of amortization|Operating profit before deduction of amortization CRSP|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|Profit before payment of interest, taxes and amortization BEAM (beamtx.com)|Operating profit EBITDA SRPT (Sarepta)|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|TXG - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Intellia Corp|STOK (Stoke Therapeutics) - Operating profit before deduction of amortization|biolifesolutions.com - Income before deduction of interest, taxes and amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Maze Therapeutics, Inc. (MAZE) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|Prime Medicine Bio - Operating profit before amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|QURE - Operating profit before deduction of amortization|MGTX: Operating profit before deduction of amortization|Operating income before deduction of amortization REGENXBIO Inc RGNX|SLDB (Solid Bio) - Operating profit before deduction of amortization|OCGN: Company profit before taxes, interest and amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNTC|Operating profit EBITDA DSGN|Operating income before deduction of amortization Rocket Pharma|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Lexeo Therapeutics Inc. (LXEO) - Profit before interest, taxes and amortization|Korro Bio, Inc - Operating profit EBITDA|EDIT (editasmedicine.com) - Operating profit before amortization|Silence Therapeutics plc (SLN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PRQR|CDXS (Codexis Inc) - Operating profit EBITDA|Operating profit EBITDA Sangamo BioSciences|Operating profit before deduction of amortization NAUT (Nautilus Biotechnology)|Company profit before taxes, interest and amortization MGX|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|Generation Bio Co (GBIO) - Profit before interest, taxes and amortization|BOLD - Profit before payment of interest, taxes and amortization|XCUR: Profit before payment of interest, taxes and amortization|IMNN: Operating profit EBITDA|Profit before interest, taxes and amortization Phio Pharmaceuticals Corp. (PHIO)|Profit before payment of interest, taxes and amortization Mustang Bio Inc|TransCode (RNAZ) - Operating income before deduction of amortization|Operating profit EBITDA BNGO|Operating income before deduction of amortization Applied DNA Corp|Profit before payment of interest, taxes and amortization bluebird bio, Inc. BLUE|Operating income before deduction of amortization ImmunoPrecise Antibodies Ltd (IPA)|OMGA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization OMIC (Singular Genomics Systems, Inc.)|RGLS: Operating profit EBITDA|SYRS (Syros Pharmaceuticals, Inc) - Profit before payment of interest, taxes and amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
